Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $43mm for CNS start-up NeuroTherapeutics

Executive Summary

First-time investors MPM Capital and SR One have co-led the $43mm Series B financing for NeuroTherapeutics Pharma Inc. (diseases caused by a hyperexcitable central nervous system). Fidelity Biosciences and Pfizer Venture Investments, other new backers, also participated along with returning shareholders Novo Ventures and Thomas McNerney & Partners. All of the new investors have contributed board members to the company.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies